Does Rinvoq Work for Ulcerative Colitis?
Rinvoq (upadacitinib), a JAK inhibitor from AbbVie, is FDA-approved for adults with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or intolerance to conventional therapies like TNF blockers or other biologics.[1] Clinical trials show it induces clinical remission and endoscopic improvement in these patients.
How Rinvoq Performs in Key Trials
In the U-ACHIEVE induction trial (Phase 3), 26% of patients on 45 mg once daily achieved clinical remission at week 8, compared to 5% on placebo. Endoscopic improvement occurred in 34% versus 4%.[2] The U-ACCOMPLISH trial showed similar results with the same dose. For maintenance, the U-ENDURE trial at 15 mg or 30 mg doses led to sustained remission in 42-52% of patients at week 52, versus 12% on placebo.[1][2]
Real-world data supports these findings, with remission rates around 30-40% in the first year for biologic-experienced patients.[3]
Who Responds Best and How Long Until Results?
Rinvoq works faster than many biologics, with symptom relief (stool frequency, rectal bleeding) often starting within 1-2 weeks and peak remission by week 8.[1] It performs best in patients naive to biologics (remission ~40%) versus those previously exposed (~20%).[2] Long-term data up to 3 years shows sustained response in over 50% who initially responded.[3]
Common Side Effects and Safety Concerns
Upper respiratory infections, anemia, and herpes zoster affect 10-20% of users. Serious risks include infections, blood clots, heart events, and malignancies, leading to a boxed warning. Monitoring for lipids, liver enzymes, and infections is required.[1] In UC trials, serious infections occurred in 3-5% versus 1% on placebo.[2]
How Rinvoq Compares to Other UC Treatments
| Treatment | Class | Week 8 Remission Rate (Induction) | Maintenance Remission (Week 52) |
|-----------|-------|-----------------------------------|---------------------------------|
| Rinvoq (45 mg induction) | JAK inhibitor | 26%[2] | 42-52%[2] |
| Stelara (ustekinumab) | IL-12/23 inhibitor | 16%[4] | 44%[4] |
| Entyvio (vedolizumab) | Integrin inhibitor | 17%[5] | 42%[5] |
| Humira (adalimumab) | TNF inhibitor | 13%[6] | 17%[6] |
Rinvoq offers higher induction rates and oral convenience but higher infection risk than gut-selective options like Entyvio.[3]
When Does Rinvoq Fail and What Are Alternatives?
Primary non-response occurs in 50-70% during induction; dose escalation to 30 mg or switching to another class (e.g., IL-23 inhibitors) helps ~30% of failures.[3] Biosimilars for TNFs provide cheaper alternatives, but Rinvoq's patent (expires ~2033 in US) blocks generics.[7]
Not for mild UC or patients with active infections—requires specialist oversight.[1]
Sources
[1]: Rinvoq Prescribing Information (FDA)
[2]: NEJM: U-ACHIEVE/U-ACCOMPLISH/U-ENDURE Trials
[3]: Gastroenterology: Real-World Effectiveness
[4]: UNIFI Trial (Stelara)
[5]: GEMINI Trial (Entyvio)
[6]: ULTRA Trials (Humira)
[7]: DrugPatentWatch: Rinvoq Patents